2013 · Ishibashi — Molecular hydrogen: new antioxidant and anti-inflammatory therapy for rheumatoid arthritis and related diseases
Super-Abstract
Reactive oxygen species (ROS) — especially the hydroxyl radical — play a central role in the joint destruction and systemic inflammation of rheumatoid arthritis (RA), and molecular hydrogen (H₂) selectively neutralizes exactly this radical. This review argues that H₂ represents a promising complement to conventional RA therapy by reducing oxidative stress at early disease stages, potentially also preventing the associated cardiovascular risk. (Current Pharmaceutical Design, 2013.)
Commentary
This is a review by Ishibashi, who is closely associated with early clinical H₂ research in rheumatoid arthritis. The paper presents a mechanistic framework: ROS and specifically hydroxyl radicals sit at the center of NF-κB and TNF-α pathways, both of which drive RA pathogenesis and the associated elevated cardiovascular risk. Standard biologic therapies (TNF-α inhibitors, IL-6 inhibitors) are effective but carry significant side effects and high cost. The author positions H₂ as an adjunct — reducing upstream oxidative stress — particularly at early disease stages where H₂ showed significant therapeutic potential in cited clinical work. Notably, early RA response to H₂ may also assist in diagnosis and treatment decisions. This paper is a narrative literature synthesis; it references early clinical trials but is not itself a clinical trial report.
Key quotes
- „Among the ROS, the hydroxyl radical is the most harmful, and molecular hydrogen (H2) is a selective scavenger for this species.“ — the mechanistic core: H₂ targets the most damaging ROS in RA
- „it has been shown that H2 is useful when administered along with the conventional therapy in RA as it acts to reduce oxidative stress in the patients.“ — H₂ as adjunct to standard RA therapy — based on early clinical evidence
- „Especially in the early stage, H2 showed significant therapeutic potential, which also seemed to assist diagnosis and treatment decisions of RA.“ — early-stage RA as the window where H₂ effect was most pronounced
Our assessment
This is a review article on H₂ in rheumatoid arthritis with a sound mechanistic rationale. It references early clinical trial data supporting H₂ as an adjunct to RA therapy — this is stronger evidence than pure animal work, but the clinical trials cited were small. The potential to also reduce RA-associated cardiovascular risk via H₂ antioxidant effects is an interesting hypothesis not yet confirmed in long-term human studies. No overstatement: H₂ is not a replacement for established RA biologics, and long-term controlled trials in RA are still needed. The review accurately characterizes the state of evidence circa 2013.
Study design
- Type: narrative review · n: n/a (literature synthesis) · H₂ delivery cited: unspecified (references to early clinical studies and in-vitro work)
- Scope: RA pathogenesis (ROS, NF-κB, TNF-α), conventional biologic therapies and their limitations, H₂ as selective ROS scavenger, RA-associated cardiovascular risk, early H₂ clinical evidence
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease in which the progressive destruction of joint causes morbidity. It is also associated with an increased risk of atherosclerosis, which can result in cardiovascular disease and mortality. The therapeutic goal is to control the systemic inflammation to obtain not only the remission of symptoms, but also improve general state of health. Although recent biologic immunosuppressive therapies targeting pro-inflammatory cytokines have spawned a paradigm shift regarding the prognosis of RA, these therapies possess inherent side effects. Also, early diagnosis of the disease remains confounded by uncertainty. While the mechanisms responsible for the onset of RA remain unclear, reactive oxygen species (ROS) play a significant role in the pathogenesis of RA. ROS play a central role both upstream and downstream of NF-κB and TNFα pathways, which are located at the center of the inflammatory response. Among the ROS, the hydroxyl radical is the most harmful, and molecular hydrogen (H2) is a selective scavenger for this species. Recently, it has been shown that H2 is useful when administered along with the conventional therapy in RA as it acts to reduce oxidative stress in the patients. Especially in the early stage, H2 showed significant therapeutic potential, which also seemed to assist diagnosis and treatment decisions of RA. The possible expectations regarding the potential benefits of H2 by reducing the oxidative stress, resulting from inflammatory factors, are raised and discussed here. They include prevention of RA and related atherosclerosis, as well as therapeutic validity for RA.
Source & links
Screenshot of the PubMed page
This page mirrors the published abstract (© the authors / publisher) for reference and citation. The canonical source is the PubMed record linked above. This is not medical advice.